Skip to content

Targeted therapy for BRAF-mutant melanoma

TL;DR — BRAF inhibition was the first targeted therapy to improve survival in metastatic melanoma: vemurafenib against dacarbazine reduced the risk of death by 63% and of progression or death by 74% (both P < .001), with 6-month overall survival 84% versus 64% (Chapman 2011, PMID 21639808); final BRIM-3 analysis gave median OS 13.6 versus 9.7 months censored at crossover (HR 0.81, 95% CI 0.67–0.98, P = .03) (Chapman 2017, PMID 28961848). Adding MEK inhibition roughly doubled the durable-benefit fraction: pooled COMBI-d/COMBI-v five-year outcomes for dabrafenib–trametinib were 19% progression-free and 34% alive at 5 years (Robert 2019, PMID 31166680), and COLUMBUS's seven-year update gave 7-year PFS 21.2% (14.7–28.4) and OS 27.4% (21.2–33.9) for encorafenib–binimetinib versus 6.4% (2.1–14.0) and 18.2% (12.8–24.3) for vemurafenib, with median melanoma-specific survival 36.8 versus 19.3 months (Schadendorf 2024, PMID 38723373). But sequencing is settled against targeted therapy going first: DREAMseq found 2-year OS 71.8% starting with nivolumab–ipilimumab versus 51.5% starting with dabrafenib–trametinib (P = .010) (Atkins 2023, PMID 36166727). Targeted therapy's distinctive properties — rapid response, activity in high-burden symptomatic disease, and predictable resistance — define its remaining role.

The registrational sequence

Trial Comparison Result
BRIM-3 (Chapman 2011, PMID 21639808; final Chapman 2017, PMID 28961848) Vemurafenib 960 mg bd vs dacarbazine 1,000 mg/m² q3w, 675 patients Interim: 63% relative reduction in risk of death, 74% in progression or death (P < .001); 6-month OS 84% vs 64%. Final (database lock August 2015): median OS 13.6 months (12.0–15.4) vs 9.7 (7.9–12.8) censored at crossover, HR 0.81 (0.67–0.98), P = .03; OS rates 56%/46% (1 yr), 30%/24% (2 yr), 21%/19% (3 yr), 17%/16% (4 yr). 51% of dacarbazine patients crossed over
COMBI-d + COMBI-v pooled (Robert 2019, PMID 31166680) Dabrafenib 150 mg bd + trametinib 2 mg od, 563 patients PFS 21% (17–24) at 4 years and 19% (15–22) at 5 years; OS 37% (33–42) at 4 years and 34% (30–38) at 5 years. Complete response in 109 patients (19%), associated with improved long-term outcome. Performance status, age, sex, number of organ sites and LDH all independently associated with both endpoints
COLUMBUS (Dummer 2018, PMID 29573941; OS analysis Dummer 2018, PMID 30219628; 7-year Schadendorf 2024, PMID 38723373) Encorafenib 450 mg od + binimetinib 45 mg bd (n = 192) vs vemurafenib 960 mg bd (n = 191) vs encorafenib 300 mg od (n = 194); 577 patients, 162 hospitals, 28 countries; treatment-naive or progressed after first-line immunotherapy 7-year PFS 21.2% (14.7–28.4) vs 6.4% (2.1–14.0); 7-year OS 27.4% (21.2–33.9) vs 18.2% (12.8–24.3); median melanoma-specific survival 36.8 months (27.7–51.5) vs 19.3 (14.8–25.9). 34 long-term responders across arms with complete or partial response ongoing at 7 years
IMspire150 (Ascierto 2023, PMID 36460017) Atezolizumab or placebo added to vemurafenib + cobimetinib, first-line BRAF V600-mutant advanced melanoma, 108 hospitals, 20 countries Second interim overall-survival analysis of the triplet

The 7-year COLUMBUS follow-up is the longest for any BRAF/MEK combination in a phase 3 trial (PMID 38723373). Its 34 long-term responders establish that targeted therapy can produce durable remissions, contradicting the older view that BRAF inhibition is uniformly a temporising measure — but the fraction is far smaller than under checkpoint blockade (see immunotherapy in advanced disease).

The sequencing question, and its randomised answer

DREAMseq (ECOG-ACRIN EA6134) randomised 265 treatment-naive BRAF V600-mutant metastatic melanoma patients to nivolumab–ipilimumab (arm A) or dabrafenib–trametinib (arm B), with crossover at progression (arms C and D):

Endpoint Immunotherapy first Targeted therapy first
2-year overall survival 71.8% (95% CI 62.5–79.1) 51.5% (41.7–60.4), log-rank P = .010
Objective response rate, first-line 46.0% 43.0%
Objective response rate, second-line 47.8% (targeted after immunotherapy) 29.6% (immunotherapy after targeted)
Median duration of response not reached 12.7 months (P < .001)

Source: Atkins 2023, PMID 36166727. The trial was stopped early by its DSMC. Crossover occurred in 52% of patients with documented progression, and grade ≥3 toxicity frequency was similar between arms. The asymmetry in second-line response rates — 47.8% versus 29.6% — is the mechanistic core of the result: targeted therapy retains activity after immunotherapy, whereas immunotherapy loses activity after targeted therapy, which is consistent with BRAF-inhibitor resistance reverting the microenvironment to a low-immunogenic state through PD-L1 induction (Proietti 2020, PMID 33003483).

Where targeted therapy is still preferred

  • Rapid symptomatic disease. Response occurs within weeks rather than months; BRIM-3's 6-month survival separation of 84% versus 64% appeared before any immunotherapy trial's curves diverged (PMID 21639808).
  • After immunotherapy failure. COLUMBUS explicitly enrolled patients who had progressed after first-line immunotherapy (PMID 30219628), and DREAMseq's arm C response rate was 47.8% (PMID 36166727).
  • Adjuvant BRAF-mutant stage III disease, where COMBI-AD halved relapse risk — see adjuvant therapy (Long 2024, PMID 38899716).
  • Neoadjuvant BRAF-mutant disease, where NeoCombi produced high pathological response rates but 60% recurrence at five years — see neoadjuvant therapy (Menzies 2024, PMID 38754780).

Resistance

Systematic review of BRAF-inhibitor resistance in melanoma identifies four domains — genetic, epigenetic/transcriptomic, immune, and combination strategies. Common resistance mutations are BRAF splice variants, BRAF amplification, NRAS mutations and MEK1/2 mutations; genetic and epigenetic changes reactivate previously blocked MAPK signalling, activate alternative pathways, and drive epithelial-to-mesenchymal transition. Once resistance develops the tumour microenvironment reverts to a low-immunogenic state secondary to PD-L1 induction. Adding a MEK inhibitor delays resistance and lengthens response duration (Proietti 2020, PMID 33003483). Further systematic reviews (Cosci 2025, PMID 40872623) and mechanistic syntheses (Shang 2026, PMID 41807883; Tangella 2021, PMID 32956754; Amaral 2017, PMID 28162869) extend the same taxonomy.

Resistance is heterogeneous within and between tumours, which defeats biopsy-guided sequential targeting. Among 59 BRAF-V600-mutant metastases progressing on dabrafenib or vemurafenib, resistance mechanisms were identified in 58%, occurred both within and between patients and tumours, were present in some pre-treatment biopsies, and MAPK activity remained inhibited in 21% of resistant tumours whose outcomes were poor. No patient responded to a subsequent targeted therapy even when the progressing biopsy carried a mechanism predicted to be sensitive (Rizos 2014, PMID 24463458). A multicentre meta-analysis has characterised the spectrum, frequency and phenotypic associations of acquired resistance mechanisms (Johnson 2015, PMID 26608120).

Non-genetic resistance runs in parallel: every melanoma profiled at single-cell resolution contained both MITF-high and MITF-low/AXL-high transcriptional states, the latter carrying a drug-resistance programme (Tirosh 2016, PMID 27124452). Cell-state-dependent heterogeneity of MAPK-inhibitor response has been demonstrated directly by single-cell RNA sequencing (PMID 39216232), and a MAFG–MITF complex and a BRN2:MYC axis have each been proposed as drivers of phenotype switching (PMID 42168173; PMID 41405996).

Non-BRAF targets

Target Status
NRAS No approved targeted agent. MEK inhibitor monotherapy has been used; real-world efficacy and safety of MEK inhibition in advanced NRAS-mutant melanoma has been reported from a Japanese single centre (PMID 41059590). NRAS-mutant tumours behave more aggressively in routine care (independent progression HR 2.01, 1.02–3.98) (Heppt 2017, PMID 28797232)
KIT Mutated in 9.5% of melanomas overall and enriched in acral, mucosal and chronically sun-damaged sites (Gong 2018, PMID 29746316). A systematic review and one-arm meta-analysis of c-KIT inhibitors in unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma summarises the evidence (Steeb 2021, PMID 34562816) — see acral and mucosal melanoma
NF1 No matched agent; MAPK activation without a druggable hotspot (Cancer Genome Atlas Network 2015, PMID 26091043)
GNAQ/GNA11 Uveal melanoma drivers; tebentafusp works by a different mechanism entirely — see uveal melanoma (Piulats 2024, PMID 38048850)
Triple wild-type Enriched for KIT mutations, focal amplifications and complex structural rearrangements (PMID 26091043)

Triplet therapy

IMspire150 added atezolizumab to vemurafenib–cobimetinib in previously untreated unresectable stage IIIc or IV BRAF V600-mutant melanoma across 108 hospitals in 20 countries, randomised 1:1 and stratified by region and baseline LDH, with atezolizumab or placebo added from cycle two (Ascierto 2023, PMID 36460017). Biomarkers of treatment benefit from the same trial have been reported separately (PMID 35131452), as has a cost-effectiveness estimate (PMID 34762112). The triplet has not displaced sequential therapy, and DREAMseq's result argues for immunotherapy-first rather than concurrent combination in most patients (PMID 36166727).

The combination-versus-single-agent trial

COMBI-v randomised 704 patients with BRAF V600-mutant metastatic melanoma to first-line dabrafenib plus trametinib or vemurafenib, with overall survival as the primary endpoint. At the preplanned interim analysis after 77% of expected events, 12-month overall survival was 72% (95% CI 67–77) with the combination versus 65% (59–70) with vemurafenib (HR for death 0.69, 0.53–0.89, P = .005); the prespecified stopping boundary was crossed and the study was stopped for efficacy in July 2014, with median progression-free survival 11.4 months in the combination arm (Robert 2015, PMID 25399551). This is the trial that established BRAF/MEK combination over BRAF inhibition alone, and the pooled COMBI-d/COMBI-v five-year follow-up above (PMID 31166680) is its long-term extension.

Single-agent BRAF inhibitor safety at scale was characterised in an open-label multicentre study reporting 3,226 enrolled patients in 44 countries between March 2011 and January 2013, with 3,222 receiving at least one dose. Common all-grade adverse events were rash (49%), arthralgia (39%), fatigue (34%) and photosensitivity reaction (Larkin 2014, PMID 24582505). The linked registration currently lists 3,219 participants rather than the publication's 3,226; the discrepancy is retained explicitly rather than silently harmonised (NCT01307397, live-checked 2026-09-01).

Toxicity, and the pyrexia problem

BRAF/MEK inhibitor toxicity is distinctive, dose-interruption-managed, and dominated by one syndrome.

Finding Detail
Pyrexia incidence Across 1,076 patients receiving dabrafenib plus trametinib in four trials (COMBI-AD n = 435, COMBI-d n = 209, COMBI-v n = 350, and an NSCLC registration trial n = 82), 61.3% developed pyrexia, 5.7% grade 3/4 and 15.6% a protocol-defined serious pyrexia event. Among the 660 with pyrexia, 33.0% had one occurrence, 19.8% two and 47.1% three or more. Incidence was highest early and fell with time on treatment; temporary dose interruption was the commonest and most effective management (Schadendorf 2021, PMID 34225229)
Managing it changes outcomes COMBI-APlus, an open-label phase 3b trial in high-risk resected stage III BRAF V600E/K melanoma, tested an adapted algorithm interrupting both drugs at temperature ≥38 °C or on suspected recurrent pyrexia syndrome and restarting at the same dose after ≥24 hours symptom-free. The composite rate of grade 3/4 pyrexia, hospitalisation for pyrexia or permanent discontinuation for pyrexia fell to 8.0% against a historical COMBI-AD control of 20.0% (95% CI 16.3–24.1) (Atkinson 2022, PMID 35042070)
Regimen differences In COLUMBUS's 570-patient safety population, median exposure was longer with encorafenib plus binimetinib (51 weeks) than encorafenib alone (31) or vemurafenib (27), and pyrexia was less frequent with encorafenib plus binimetinib (18%); common BRAFi/MEKi toxicities were generally manageable, reversible and infrequently caused discontinuation (Gogas 2019, PMID 31437754)
General management Tolerability of BRAF/MEK combinations and management of MAPK-pathway adverse events have been reviewed (PMID 31231568; Daud 2017, PMID 28526719; PMID 29149136)

The pyrexia result is unusual and worth stating plainly: a management algorithm, tested prospectively in a phase 3b trial, more than halved a composite toxicity endpoint without changing the drug or the dose. Very little else in melanoma toxicity management has that level of evidence — contrast the consensus basis of the immune-toxicity guidance in immune-related adverse events.

Interpretation rules for this page

  • Crossover inflates the control arm. 51% of BRIM-3 dacarbazine patients crossed over to vemurafenib; report both censored and uncensored estimates (PMID 28961848).
  • Single-agent BRAF inhibition is obsolete as a comparator — COLUMBUS's vemurafenib arm is a historical control by modern standards (PMID 38723373).
  • Long-term targeted-therapy benefit exists but is small: 21.2% 7-year PFS with encorafenib–binimetinib, 34 long-term responders across all three arms (PMID 38723373).
  • Sequence changes outcome more than agent choice does (PMID 36166727).
  • A resistance mechanism identified on a progressing biopsy does not predict response to the matched next agent (PMID 24463458).
  • Non-genetic (phenotype-switching) resistance coexists with mutational resistance and is not detected by sequencing (PMID 27124452).

Open questions

  • Can any patient be identified prospectively as a candidate for targeted therapy first, given DREAMseq's population-level answer (PMID 36166727)?
  • What distinguishes the 34 COLUMBUS long-term responders from the rest (PMID 38723373)?
  • Is there a role for intermittent or drug-holiday dosing to delay resistance, and has it been tested in a phase 3 trial (PMID 33003483)?
  • Can MITF-low/AXL-high phenotype switching be targeted, or only described (PMID 27124452; PMID 42168173)?
  • Is there any effective targeted approach for NRAS-mutant melanoma (PMID 28797232)?
  • Does triplet therapy have a defined population after DREAMseq (PMID 36460017; PMID 36166727)?

References

  1. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507-16. PMID 21639808
  2. Chapman PB, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28:2581-2587. PMID 28961848
  3. Robert C, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England journal of medicine. 2019;381:626-636. PMID 31166680
  4. Schadendorf D, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European journal of cancer (Oxford, England : 1990). 2024;204:114073. PMID 38723373
  5. Atkins MB, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41:186-197. PMID 36166727
  6. Dummer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. 2018;19:603-615. PMID 29573941
  7. Dummer R, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2018;19:1315-1327. PMID 30219628
  8. Ascierto PA, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. The Lancet. Oncology. 2023;24:33-44. PMID 36460017
  9. Proietti I, et al. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers. 2020;12. PMID 33003483
  10. Long GV, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England journal of medicine. 2024;391:1709-1720. PMID 38899716
  11. Menzies AM, et al. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2024;35:739-746. PMID 38754780
  12. Cosci I, et al. Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Pharmaceuticals (Basel, Switzerland). 2025;18. PMID 40872623
  13. Shang Y, et al. BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. Molecular biomedicine. 2026;7. PMID 41807883
  14. Tangella LP, et al. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica et biophysica acta. General subjects. 2021;1865:129736. PMID 32956754
  15. Amaral T, et al. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. European journal of cancer (Oxford, England : 1990). 2017;73:93-101. PMID 28162869
  16. Rizos H, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:1965-77. PMID 24463458
  17. Johnson DB, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European journal of cancer (Oxford, England : 1990). 2015;51:2792-9. PMID 26608120
  18. Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 2016;352:189-96. PMID 27124452
  19. Lim SY, et al. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine. 2024;107:105308. PMID 39216232
  20. Vera O, et al. A MAFG~MITF complex drives melanoma phenotype switching and progression. Nature communications. 2026;17. PMID 42168173
  21. Zhang Y, et al. A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell reports. 2025;44:116675. PMID 41405996
  22. Nakano E, et al. Real-World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS-Mutant Melanoma: A Single-Center Retrospective Study in Japan. The Journal of dermatology. 2025;52:1897-1901. PMID 41059590
  23. Heppt MV, et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC cancer. 2017;17:536. PMID 28797232
  24. Gong HZ, et al. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma research. 2018;28:259-270. PMID 29746316
  25. Steeb T, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. European journal of cancer (Oxford, England : 1990). 2021;157:348-357. PMID 34562816
  26. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-96. PMID 26091043
  27. Piulats JM, et al. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2024;35:317-326. PMID 38048850
  28. Robert C, et al. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF(V600) mutation-positive melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2022;33:544-555. PMID 35131452
  29. Cai C, et al. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma. JAMA network open. 2021;4:e2132262. PMID 34762112
  30. Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015;372:30-9. PMID 25399551
  31. Larkin J, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet. Oncology. 2014;15:436-44. PMID 24582505
  32. Schadendorf D, et al. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European journal of cancer (Oxford, England : 1990). 2021;153:234-241. PMID 34225229
  33. Atkinson V, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European journal of cancer (Oxford, England : 1990). 2022;163:79-87. PMID 35042070
  34. Gogas HJ, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European journal of cancer (Oxford, England : 1990). 2019;119:97-106. PMID 31437754
  35. Heinzerling L, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO open. 2019;4:e000491. PMID 31231568
  36. Daud A, et al. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist. 2017;22:823-833. PMID 28526719
  37. Rubin KM. MAPK Pathway-Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. Clinical journal of oncology nursing. 2017;21:699-709. PMID 29149136